We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




New Urinalysis Solution Improves Laboratory Workflow by Reducing Manual Reviews and Sample Processing Time

By LabMedica International staff writers
Posted on 05 Oct 2021
Print article
Image: DxU Iris Workcell Urinalysis Solution (Photo courtesy of Beckman Coulter, Inc.)
Image: DxU Iris Workcell Urinalysis Solution (Photo courtesy of Beckman Coulter, Inc.)

Beckman Coulter, Inc. (Brea, CA, USA) has launched the DxU Iris Workcell, its new fully automated system that streamlines urinalysis workflow and reduces manual reviews to 4%.

A routine urinalysis is one the most frequently ordered tests, representing up to 30% of all samples received in the lab. Many of these samples require a lab technician to perform a manual inspection, which causes workflow disruption and a substantial increase in workload. Whether it is confirming the analyzer's findings or identifying unique particle types, manual microscopic reviews are time-consuming and can take up to six times longer per sample than with an automated system. Automating the routine urinalysis workflow with the DxU Iris Workcell reduces sample subjectivity and variability, helping laboratories of all sizes standardize processes, drive faster turnaround time and deliver quality results.

The DxU Iris Workcell pairs the DxU 850m Iris or DxU 840m Iris urine microscopy analyzer with the Arkray AUTION MAX 4030 urine chemistry analyzer to create a scalable, fully automated urinalysis solution. The workcell was developed with proprietary Digital Flow Morphology technology with Auto-Particle Recognition (APR) Software to enable laboratories to deliver standardized results using artificial intelligence (AI). This industry-leading technology isolates, identifies and characterizes urine particles to provide immediate, accurate and reproducible results verified directly on the screen.

"There is no doubt that the pandemic has intensified pressure on the clinical laboratory," said Dr. Peter Soltani, senior vice president & general manager, hematology, urinalysis & workflow information technology solutions at Beckman Coulter. "In this pressurized environment, manual reviews are particularly onerous because they are labor-intensive, taking time and focus away from scientific work. We designed the DxU Iris Workcell to allow urinalysis operators to automatically classify sediment particles, minimizing the need for human intervention."

Related Links:
Beckman Coulter, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.